CBD Life Sciences Inc. (CBDL) has launched an innovative line of CBD-infused vaginal and rectal suppositories, entering the $2.8 billion suppository market. The product aims to provide targeted relief for conditions including menstrual cramps, endometriosis, pelvic floor dysfunction, and gastrointestinal discomfort. The suppositories offer superior bioavailability compared to oral CBD products by delivering CBD directly into the bloodstream through the pelvic region or lower bowel. The global pharmaceutical suppositories market, valued at $1.6 billion in 2022, is projected to grow at a 5.7% CAGR to reach $2.8 billion by 2032, with North America holding the largest market share. Local healthcare professionals in Scottsdale, Arizona, have shown interest in the therapeutic potential of these suppositories, validating the product's market readiness.
CBD Life Sciences Inc. (CBDL) ha lanciato una linea innovativa di supposte vaginali e rettali infuse con CBD, entrando nel mercato delle supposte da 2,8 miliardi di dollari. Il prodotto mira a offrire un sollievo mirato per condizioni come crampi mestruali, endometriosi, disfunzioni del pavimento pelvico e fastidi gastrointestinali. Le supposte garantiscono una biodisponibilit脿 superiore rispetto ai prodotti orali a base di CBD, grazie alla somministrazione diretta nel flusso sanguigno attraverso la regione pelvica o l'intestino inferiore. Il mercato globale delle supposte farmaceutiche, valutato 1,6 miliardi di dollari nel 2022, 猫 previsto crescere con un CAGR del 5,7% fino a raggiungere i 2,8 miliardi entro il 2032, con il Nord America che detiene la quota di mercato pi霉 ampia. I professionisti sanitari locali di Scottsdale, Arizona, hanno mostrato interesse nel potenziale terapeutico di queste supposte, confermando la prontezza del prodotto per il mercato.
CBD Life Sciences Inc. (CBDL) ha lanzado una innovadora l铆nea de supositorios vaginales y rectales infusionados con CBD, ingresando al mercado de supositorios valorado en 2.800 millones de d贸lares. El producto busca proporcionar alivio espec铆fico para condiciones como calambres menstruales, endometriosis, disfunci贸n del suelo p茅lvico y molestias gastrointestinales. Los supositorios ofrecen una biodisponibilidad superior en comparaci贸n con los productos orales de CBD al entregar el CBD directamente en el torrente sangu铆neo a trav茅s de la regi贸n p茅lvica o el intestino inferior. El mercado global de supositorios farmac茅uticos, valorado en 1.600 millones de d贸lares en 2022, se proyecta que crezca a una tasa compuesta anual del 5,7% hasta alcanzar los 2.800 millones para 2032, con Am茅rica del Norte como la mayor cuota de mercado. Los profesionales de la salud locales en Scottsdale, Arizona, han mostrado inter茅s en el potencial terap茅utico de estos supositorios, validando la preparaci贸n del producto para el mercado.
CBD Life Sciences Inc. (CBDL) a lanc茅 une gamme innovante de suppositoires vaginaux et rectaux infus茅s au CBD, entrant ainsi sur le march茅 des suppositoires estim茅 脿 2,8 milliards de dollars. Ce produit vise 脿 offrir un soulagement cibl茅 pour des affections telles que les crampes menstruelles, l鈥檈ndom茅triose, les dysfonctionnements du plancher pelvien et les inconforts gastro-intestinaux. Les suppositoires offrent une biodisponibilit茅 sup茅rieure par rapport aux produits oraux 脿 base de CBD en d茅livrant directement le CBD dans la circulation sanguine via la r茅gion pelvienne ou le bas de l鈥檌ntestin. Le march茅 mondial des suppositoires pharmaceutiques, 茅valu茅 脿 1,6 milliard de dollars en 2022, devrait cro卯tre 脿 un taux annuel moyen de 5,7 % pour atteindre 2,8 milliards d鈥檌ci 2032, l鈥橝m茅rique du Nord d茅tenant la plus grande part de march茅. Les professionnels de sant茅 locaux de Scottsdale, en Arizona, ont manifest茅 un int茅r锚t pour le potentiel th茅rapeutique de ces suppositoires, validant ainsi la pr茅paration du produit pour le march茅.
CBD Life Sciences Inc. (CBDL) hat eine innovative Produktlinie von mit CBD angereicherten vaginalen und rektalen Z盲pfchen auf den Markt gebracht und betritt damit den 2,8 Milliarden Dollar schweren Z盲pfchenmarkt. Das Produkt zielt darauf ab, gezielte Linderung bei Beschwerden wie Menstruationskr盲mpfen, Endometriose, Beckenbodenfunktionsst枚rungen und gastrointestinalen Beschwerden zu bieten. Die Z盲pfchen bieten eine 眉berlegene Bioverf眉gbarkeit im Vergleich zu oralen CBD-Produkten, indem sie CBD direkt 眉ber den Beckenbereich oder den unteren Darm in den Blutkreislauf abgeben. Der weltweite Markt f眉r pharmazeutische Z盲pfchen, der 2022 mit 1,6 Milliarden Dollar bewertet wurde, soll mit einer j盲hrlichen Wachstumsrate von 5,7 % auf 2,8 Milliarden Dollar bis 2032 wachsen, wobei Nordamerika den gr枚脽ten Marktanteil h盲lt. Lokale Gesundheitsfachkr盲fte in Scottsdale, Arizona, haben Interesse am therapeutischen Potenzial dieser Z盲pfchen gezeigt und damit die Marktreife des Produkts best盲tigt.
Positive
Entry into a growing $2.8 billion suppository market with significant growth potential
Superior product bioavailability compared to traditional oral CBD products
Addresses multiple medical conditions and markets (women's health, men's health, gastrointestinal therapy)
Strong local medical community interest and endorsement
North American market dominance aligns with company's operational region
Negative
Entering a highly regulated pharmaceutical market which may require additional compliance
Product acceptance may face challenges due to administration method
Competition from established pharmaceutical companies in the suppository market
CBDL Enters the $2.8 Billion Suppository Market with a First-of-Its-Kind Product - Tapping a High-Demand, Low-Competition Sector Poised for Transformational Growth
SCOTTSDALE, AZ / / June 3, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leader in the CBD wellness industry, proudly announces the launch of its groundbreaking line of CBD-infused vaginal and rectal suppositories. This innovative product is poised to transform the landscape of women's health by offering targeted relief for a myriad of conditions, including menstrual cramps, endometriosis, pelvic floor dysfunction, and gastrointestinal discomfort.
A Breakthrough for Localized, Fast-Acting Relief
Unlike oral CBD products, which must pass through the digestive system and may lose potency in the process, suppositories offer rapid absorption and superior bioavailability by delivering CBD directly into the bloodstream through the pelvic region or lower bowel.
This method allows patients to experience faster, more concentrated relief, particularly for conditions like:
Endometriosis and menstrual pain
Pelvic floor dysfunction
Prostatitis and hemorrhoids
Gastrointestinal disorders (IBS, IBD, Crohn's)
Chronic pelvic pain syndrome
Post-surgical recovery inflammation
By formulating this unique delivery system, CBD Life Sciences Inc. is opening the door to a broader application of CBD - bridging gaps in women's health, men's health, and gastrointestinal therapy.
The Science Behind the Relief
Recent studies show that CBD's anti-inflammatory, analgesic, and antispasmodic properties make it uniquely suited for conditions involving chronic pelvic or intestinal tension. In rectal use, CBD interacts with local CB1 and CB2 receptors in the digestive tract to reduce inflammation and modulate pain responses. For vaginal use, CBD has shown promise in reducing pelvic muscle tightness, cramping, and discomfort associated with reproductive or bladder-related disorders.
Market Potential: A Billion-Dollar Opportunity
The global pharmaceutical suppositories market was valued at approximately $1.6 billion in 2022 and is projected to reach $2.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7% . North America holds the largest market share, accounting for nearly two-fifths of the global revenue.
CBD Life Sciences Inc.'s entry into this burgeoning market positions the company at the forefront of a healthcare revolution, offering investors a unique opportunity to capitalize on the intersection of natural wellness and women's health.
Local Medical Community Endorsement
Several healthcare professionals in Scottsdale, Arizona, have approached CBD Life Sciences Inc., expressing keen interest in the therapeutic potential of these suppositories for their patients. This local engagement underscores the product's relevance and anticipated impact in the medical community, further validating its market readiness and clinical significance.
About CBD Life Sciences Inc. (CBDL) CBD Life Sciences Inc. is a vertically integrated health and wellness company focused on cannabinoid innovation. With a robust pipeline of CBD, Delta-8, and other hemp-derived formulations, CBDL operates across direct-to-consumer, retail, and wholesale channels - including recent distribution on Walmart Marketplace and additional platforms coming soon.
Follow our social media for the latest updates! X: Instagram: IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information Lisa Nelson CEO
4802091720
SOURCE: CBD Life Sciences Inc.
View the original on ACCESS Newswire
FAQ
What is the market size for CBD Life Sciences' new suppository product?
The global pharmaceutical suppositories market is projected to reach $2.8 billion by 2032, growing at a 5.7% CAGR from $1.6 billion in 2022.
What medical conditions does CBDL's new CBD suppository target?
The product targets conditions including menstrual cramps, endometriosis, pelvic floor dysfunction, prostatitis, hemorrhoids, gastrointestinal disorders, and chronic pelvic pain syndrome.
How do CBDL's CBD suppositories differ from oral CBD products?
The suppositories offer faster absorption and superior bioavailability by delivering CBD directly into the bloodstream through the pelvic region or lower bowel, unlike oral products that must pass through the digestive system.
What is the geographic focus of CBDL's suppository market?
North America holds the largest market share, accounting for nearly two-fifths of the global suppository market revenue.
Has CBDL received any medical community support for their new product?
Yes, several healthcare professionals in Scottsdale, Arizona have expressed keen interest in the therapeutic potential of these suppositories for their patients.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
